{"entity":{"id":"nct06432296","kind":"trial","name":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","aka":[],"tldr":"A phase 3 trial of M701 run by Wuhan YZY Biopharma Co., Ltd., active.","summary":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody is a phase 3 interventional study registered as NCT06432296 by Wuhan YZY Biopharma Co., Ltd., with 312 participants enrolled, started 2024-03-25. Conditions listed: Malignant Ascites. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06432296","url":"https://clinicaltrials.gov/study/NCT06432296"}],"tags":["ctgov-ingest"],"related":[],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":["m701"],"companies":["wuhan-yzy-biopharma"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06432296","phase":"3","setting":"A Randomized, Controlled, Multi-Center Phase III Clinical Study to Evaluate the Efficacy and Safety of M701 for Intraperitoneal Injection in Patients With Malignant Ascites Caused by Advanced Epithelial Solid Tumors","sponsor":"Wuhan YZY Biopharma Co., Ltd.","enrolled":312,"outcomes":[]},"route":"/trials/nct06432296/","neighbours":{"drug":[{"id":"m701","kind":"drug","name":"M701","route":"/drugs/m701/"}],"company":[{"id":"wuhan-yzy-biopharma","kind":"company","name":"Wuhan YZY Biopharma","route":"/companies/wuhan-yzy-biopharma/"}]}}